Supreme Court Grants Review of Federal Circuit’s Rule Applying On-Sale Bar for “Secret Sales”

  • June 30, 2018
  • Category: Biotech and Pharma, Patent Litigation Feature

The US Supreme Court has agreed to review the Federal Circuit’s controversial rule that allows the disclosure of confidential sales to trigger the on-sale bar. Under 35 USC Section 102(a), as amended by the America Invents Act (AIA), a patent cannot be granted if the claimed invention was “on sale, or otherwise available to the public” outside of a one-year grace period before the “effective filing date” of the patent. In May 2017, the Federal Circuit ruled in Helsinn Healthcare v. Teva Pharmaceuticals that this restriction, known as the on-sale bar, applies when a confidential sale of a patented invention is publicly disclosed even when the invention itself remains a secret, declining to rehear that decision en banc in March 2018. On June 25, the Supreme Court granted a petition for writ of certiorari filed by Helsinn Healthcare that challenges the Federal Circuit’s ruling. The petitioner criticized that holding for “cast[ing] substantial doubt on countless patents issued pursuant to” the USPTO’s post-AIA guidance, which stated that disclosures must make an invention available to the public for the bar to apply and that it is also not triggered by an inventor’s confidential disclosures to a third party.


View full article with free 30-day trial
($79/month thereafter)


  • Over 7,000 news articles covering new patent cases, key policy decisions, and USPTO assignments
  • Advanced custom alerts for campaigns and entities
  • Proprietary litigation timelines
  • Full access to Federal Circuit, PTAB, and ITC dockets
  • Judge, venue, and law firm analytics



×
×

Thank you for your feedback

×
×